HLA-B27 Testing in Axial Spondyloarthritis Diagnosis
HLA-B27 testing serves as a valuable screening tool to identify patients who warrant rheumatology referral, but a negative result should never be used to rule out axial spondyloarthritis. 1
Diagnostic Role and Limitations
HLA-B27 functions primarily as a screening parameter rather than a diagnostic test. The most recent NICE guidelines explicitly state that spondyloarthritis cannot be ruled out based solely on negative HLA-B27 results 1. This is critical because:
- Approximately 10-40% of axSpA patients are HLA-B27 negative 1, 2
- The disease occurs equally in men and women, regardless of HLA-B27 status 1
- Axial spondyloarthritis is possible even without radiographic sacroiliitis 1
When to Order HLA-B27 Testing
Order HLA-B27 testing in patients with:
- Chronic back pain lasting >3 months
- Age of symptom onset <45 years
- AND at least 3 of the following clinical features:
- Back pain onset before age 35
- Waking at night to alleviate symptoms
- Buttock pain
- Pain improvement with movement or within 2 days of NSAID use
- First-degree family member with spondyloarthritis
- Current or previous arthritis, enthesitis, or psoriasis 1
Performance Characteristics
HLA-B27 demonstrates strong screening utility with:
- Sensitivity: 90% (only 10% of patients missed) 3
- Specificity: 88-90% 3, 4
- Positive likelihood ratio: 9 3
- Post-test probability: 32% (meaning only 3 HLA-B27-positive patients need rheumatology evaluation to diagnose 1 case of axSpA) 3
These characteristics make HLA-B27 superior to inflammatory markers (ESR/CRP have only 50% sensitivity) 3 and more practical than imaging for initial screening 3.
Clinical Algorithm for Referral
Refer to rheumatology if the patient meets ALL of:
- Back pain since before age 45 years
- Duration >3 months
- EITHER:
- ≥4 clinical features listed above, OR
- ≥3 clinical features PLUS HLA-B27 positive 1
Critical Pitfalls to Avoid
Never exclude axSpA based on:
- Negative HLA-B27 alone 1
- Normal inflammatory markers (CRP/ESR) 1
- Absence of radiographic sacroiliitis 1
The combination of these negative tests does not rule out disease. HLA-B27-negative patients may have:
- Different genetic pathways (ERAP1 polymorphisms are only associated with HLA-B27-positive disease) 5
- Higher prevalence in non-White populations 2
- More peripheral manifestations 2
- Similar diagnostic delays as HLA-B27-positive patients 6
Practical Considerations
HLA-B27 testing is cost-effective when used appropriately. The test costs approximately equivalent to a chest or pelvic X-ray, needs to be performed only once in a lifetime, and has <5% false positive/negative rate 3. Flow cytometry is acceptable for initial screening in resource-limited settings, with PCR reserved for negative results when clinical suspicion remains high 7.
Positive Test Interpretation
A positive HLA-B27 result:
- Increases likelihood of peripheral spondyloarthritis 1
- Predicts worse prognosis 3
- Supports earlier referral even with fewer clinical features 1
- Does not confirm diagnosis (requires rheumatology evaluation with imaging and clinical assessment) 1
The key principle: HLA-B27 is a "rule-in" tool for referral, never a "rule-out" tool for diagnosis.